131 related articles for article (PubMed ID: 16029291)
21. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
22. [Treatment opportunity and strategy for recurrent ovarian cancer].
Pan LY; Jin Y; Huang HF; Shen K; Wu M; Lang JH
Ai Zheng; 2003 Nov; 22(11):1188-92. PubMed ID: 14613650
[TBL] [Abstract][Full Text] [Related]
23. [Significance of the sequence of therapeutic procedures in the combined treatment of ovarian cancer patients (based on the criterion of the onset and duration or remission)].
Zadontseva NS
Vopr Onkol; 1985; 31(12):57-61. PubMed ID: 4082509
[TBL] [Abstract][Full Text] [Related]
24. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990.
Venesmaa P
Obstet Gynecol; 1994 Jul; 84(1):8-11. PubMed ID: 8008329
[TBL] [Abstract][Full Text] [Related]
25. Outcome of recurrent and persistent disease of malignant ovarian germ cell tumor: a retrospective analysis at King Chulalongkorn Memorial Hospital.
Lertkhachonsuk R; Manchana T; Termrungruanglert W; Vasuratna A; Sittisomwong T; Worasethsin P; Sirisabya N; Khemapech N; Tresukosol D
J Med Assoc Thai; 2006 Feb; 89(2):138-44. PubMed ID: 16578998
[TBL] [Abstract][Full Text] [Related]
26. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
27. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
28. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
29. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
30. Gynecologic malignancies.
Schilder RJ; Scher RM; Young RC
Cancer Chemother Biol Response Modif; 1993; 14():530-56. PubMed ID: 8312118
[TBL] [Abstract][Full Text] [Related]
31. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
32. Update on the management of ovarian cancer.
Ozols RF
Cancer J; 2002; 8 Suppl 1():S22-30. PubMed ID: 12075699
[TBL] [Abstract][Full Text] [Related]
33. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.
Chua DT; Wei WI; Sham JS; Cheng AC; Au G
Head Neck; 2003 Jul; 25(7):585-94. PubMed ID: 12808662
[TBL] [Abstract][Full Text] [Related]
34. Second-line chemotherapy of epithelial ovarian cancer.
Markmon M
Expert Rev Anticancer Ther; 2003 Feb; 3(1):31-6. PubMed ID: 12597347
[TBL] [Abstract][Full Text] [Related]
35. Medical treatment of epithelial ovarian cancer.
González-Martín AJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
[TBL] [Abstract][Full Text] [Related]
36. Epithelial ovarian cancer: second and third line chemotherapy (review).
Latorre A; De Lena M; Catino A; Crucitta E; Sambiasi D; Guida M; Misino A; Lorusso V
Int J Oncol; 2002 Jul; 21(1):179-86. PubMed ID: 12063566
[TBL] [Abstract][Full Text] [Related]
37. [The postoperative therapy of epithelial ovarian carcinoma. Has systemic cytostasis replaced percutaneous radiation?].
Souchon R; Cwiekala M
Strahlenther Onkol; 1995 Nov; 171(11):630-40. PubMed ID: 7502226
[TBL] [Abstract][Full Text] [Related]
38. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
39. Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients?
Güth U; Huang DJ; Schötzau A; Wight E
Arch Gynecol Obstet; 2010 Feb; 281(2):339-44. PubMed ID: 19554341
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience.
Carmignani CP; Sugarbaker PH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):477-87. PubMed ID: 15161446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
